Neuroprotection: where to now?

• Dirnagl U , IadecolaC, MoskowitzMA: Pathobiology of ischaemic stroke: an integrated view.Trends Neurosci.22, 391–397 (1999).
   PubMed Web of Science ®Google Scholar
• Green AR , ShuaibA: Therapeutic strategies for the treatment of stroke.Drug Discov. Today11, 681–693 (2006).
   PubMed Web of Science ®Google Scholar
• Hossmann KA : Pathophysiology and therapy of experimental stroke.Cell. Mol. Neurobiol.26, 1055–1081 (2006).
   Web of Science ®Google Scholar
• Liu R , SuzukiA, GuoZ, MizunoY, Urabe T: Intrinsic and extrinsic erythropoietin enhances neuroprotection against ischemia and reperfusion injuryin vitro.J. Neurochem.96, 1101–1110 (2006).
   PubMed Web of Science ®Google Scholar
• Ransom BR , StysPK, WaxmanSG: The pathophysiology of anoxic injury in central nervous system white matter.Stroke21, III52–III57 (1990).
   PubMed Web of Science ®Google Scholar
• Ho PW , ReutensDC, PhanTGet al.: Is white matter involved in patients entered into typical trials of neuroprotection?Stroke36, 2742–2744 (2005).
   PubMed Web of Science ®Google Scholar
• Gelmers HJ , GorterK, de Weerdt CJ, Wiezer HJ: A controlled trial of nimodipine in acute ischemic stroke. N. Engl. J. Med.318, 203–207 (1988).
   PubMed Web of Science ®Google Scholar
• Mohr JP , OrgogozoJM, HarrisonMJGet al.: Metaanalysis of oral nimodipine trials in acute ischemic stroke. Cerebrovasc. Dis.4, 197–203 (1994).
   Web of Science ®Google Scholar
• Krams M , LeesKR, HackeWet al.: Acute stroke therapy by inhibition of neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke.Stroke34, 2543–2548 (2003).
   PubMed Web of Science ®Google Scholar
• Stroke Therapy Academic Industry Roundtable II: Recommendations for clinical trial evaluation of acute stroke therapies. Stroke32, 1598–1606 (2001).
   PubMed Web of Science ®Google Scholar
• Fisher M : Recommendations for advancing development of acute stroke therapies: Stroke Therapy Academic Industry Roundtable 3.Stroke34, 1539–1546 (2003).
   PubMed Web of Science ®Google Scholar
• Stroke Therapy Academic Industry Roundtable: recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke30, 2752–2758 (1999).
   PubMed Web of Science ®Google Scholar
• Fisher M , AlbersGW, DonnanGAet al.: Enhancing the development and approval of acute stroke therapies: stroke therapy academic industry roundtable.Stroke36, 1808–1813 (2005).
   PubMed Web of Science ®Google Scholar
• Fisher M , HanleyDF, HowardG, JauchEC, WarachS: Recommendations from the STAIR V meeting on acute stroke trials, technology and outcomes.Stroke38, 245–248 (2007).
   PubMed Web of Science ®Google Scholar
• Kuroda S , TsuchidateR, SmithML, Maples KR, Siesjo BK: Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat. J. Cereb. Blood Flow Metab.19, 778–787 (1999).
   PubMed Web of Science ®Google Scholar
• Marshall JW , DuffinKJ, GreenAR, Ridley RM: NXY-059, a free radical-trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke32, 190–198 (2001).
   PubMed Web of Science ®Google Scholar
• Zhao Z , ChengM, MaplesKR, MaJY, BuchanAM: NXY-059, a novel free radical trapping compound, reduces cortical infarction after permanent focal cerebral ischemia in the rat.Brain Res.909, 46–50 (2001).
   PubMed Web of Science ®Google Scholar
• Lapchak PA , AraujoDM, SongDet al.: Effects of the spin trap agent disodium- ([tert-butylimino]methyl)benzene-1,3-disulfonate N-oxide (generic NXY-059) on intracerebral hemorrhage in a rabbit large clot embolic stroke model: combination studies with tissue plasminogen activator.Stroke33, 1665–1670 (2002).
   PubMed Web of Science ®Google Scholar
• Lapchak PA , AraujoDM, SongD, WeiJ, ZivinJA: Neuroprotective effects of the spin trap agent disodium-([tert-butylimino]methyl)benzene-1,3-disulfonate n-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator.Stroke33, 1411–1415 (2002).
   PubMed Web of Science ®Google Scholar
• Sydserff SG , BorelliAR, GreenAR, Cross AJ: Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window. Br. J. Pharmacol.135, 103–112 (2002).
   PubMed Web of Science ®Google Scholar
• Marshall JW , CummingsRM, BowesLJ, RidleyRM, GreenAR: Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion.Stroke34, 2228–2233 (2003).
   PubMed Web of Science ®Google Scholar
• Lapchak PA , SongD, WeiJ, ZivinJA: Coadministration of NXY-059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores.Exp. Neurol.188, 279–285 (2004).
   PubMed Web of Science ®Google Scholar
• Marshall JW , GreenAR, RidleyRM: Comparison of the neuroprotective effect of clomethiazole, AR-R15896AR and NXY-059 in a primate model of stroke using histological and behavioural measures.Brain Res.972, 119–126 (2003).
   PubMed Web of Science ®Google Scholar
• Jonsson S , ChengYF, EdeniusCet al.: Population pharmacokinetic modelling and estimation of dosing strategy for NXY-059, a nitrone being developed for stroke.Clin. Pharmacokinet.44, 863–878 (2005).
   PubMed Web of Science ®Google Scholar
• O‘Collins VE , MacleodMR, DonnanGAet al.: 1,026 experimental treatments in acute stroke. Ann. Neurol.59, 467–477 (2006).
   PubMed Web of Science ®Google Scholar
• Lees KR , ZivinJA, AshwoodTet al.: NXY-059 for acute ischemic stroke.N. Engl. J. Med.354, 588–600 (2006).
   PubMed Web of Science ®Google Scholar
• Macleod MR , O‘CollinsT, HowellsDW, DonnanGA: Pooling of animal experimental data reveals influence of study design and publication bias.Stroke35, 1203–1208 (2004).
   PubMed Web of Science ®Google Scholar
• Waterston RH , Lindblad-TohK, BirneyEet al.: Initial sequencing and comparative analysis of the mouse genome. Nature420, 520–562 (2002).
   PubMed Web of Science ®Google Scholar
• Savitz SI : A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke.Exp. Neurol.205, 20–25 (2007).
   PubMed Web of Science ®Google Scholar
• Werth JL , ParkTS, SilbergeldDL, Rothman SM: Excitotoxic swelling occurs in oxygen and glucose deprived human cortical slices. Brain Res.782, 248–254 (1998).
   PubMed Web of Science ®Google Scholar
• Pei Z , CheungRT: Melatonin protects SHSY5Y neuronal cells but not cultured astrocytes from ischemia due to oxygen and glucose deprivation.J. Pineal Res.34, 194–201 (2003).
   PubMed Web of Science ®Google Scholar
• Osborne NN , NashMS, WoodJP: Melatonin counteracts ischemia-induced apoptosis in human retinal pigment epithelial cells.Invest. Ophthalmol. Vis. Sci.39, 2374–2383 (1998).
   PubMed Web of Science ®Google Scholar
• Donnan GA , BaronJC, DavisSM, SharpF: Definition of the ischaemic penumbra. In: The Ischaemic Penumbra: History, Current Status and Implications for Therapy. DonnanGA, BaronJC, DavisSM, SharpF (Eds). Informa Healthcare, NY, USA7–20 (2007).
   Google Scholar
• Donnan G : A new road map for neuroprotection: the Feinberg lecture.Stroke (2007) (In press).
   Web of Science ®Google Scholar
• Moher D , SchulzKF, AltmanDG: The consort statement: revised recommendations for improving the quality of reports of parallel-group randomised trials.Lancet357, 1191–1194 (2001).
   PubMed Web of Science ®Google Scholar
• Perel P , RobertsI, SenaEet al.: Comparison of treatment effects between animal experiments and clinical trials: systematic review.BMJ334, 197 (2007).
   Google Scholar
• Davis SM , LeesKR, AlbersGWet al.: Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist.Stroke31, 347–354 (2000).
   PubMed Web of Science ®Google Scholar
• Lo EH , BroderickJP, MoskowitzMA: TPA and proteolysis in the neurovascular unit.Stroke35, 354–356 (2004).
   PubMed Web of Science ®Google Scholar
• Cohen-Gadol AA , BradleyCC, Williamson Aet al.: Normal magnetic resonance imaging and medial temporal lobe epilepsy: the clinical syndrome of paradoxical temporal lobe epilepsy. J. Neurosurg.102, 902–909 (2005).
   PubMed Web of Science ®Google Scholar
• Barrett KM , BrottTG: Carotid artery stenting versus carotid endarterectomy: current status.Neurol. Clin.24, 681–695 (2006).
   PubMed Web of Science ®Google Scholar
• Donnan GA , DavisSM: Neuroimaging, the ischaemic penumbra, and selection of patients for acute stroke therapy.Lancet Neurol.1, 417–425 (2002).
   PubMed Web of Science ®Google Scholar
• Johnston SC , RothwellPM, Nguyen-HuynhMNet al.: Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack.Lancet369, 283–292 (2007).
   PubMed Web of Science ®Google Scholar
• Ransom BR , FernR: Does astrocytic glycogen benefit axon function and survival in CNS white matter during glucose deprivation?Glia21, 134–141 (1997).
   Google Scholar
• Hacke W , AlbersG, Al-RawiYet al.: The desmoteplase in acute ischemic stroke trial (DIAS): a Phase II MRI-based 9-h window acute stroke thrombolysis trial with intravenous desmoteplase.Stroke36, 66–73 (2005).
   PubMed Web of Science ®Google Scholar
• Phan TG , DonnanGA, DavisSM, Byrnes G: Proof-of-principle Phase II MRI studies in stroke: sample size estimates from dichotomous and continuous data. Stroke37, 2521–2525 (2006).
   PubMed Web of Science ®Google Scholar

Websites

• Saver J: FAST-Mag trial. The Internet Stroke Center. Accessed on 15th May 2007 www.strokecenter.org/trials/TrialDetail.aspx?tid=449
   Google Scholar
• AstraZeneca. SAINT II trial results. http://www.astrazeneca.com/pressrelease/5279.aspx
   Google Scholar